Business as Usual – Pfizer and its $1390 drug

In today’s episode of Real Doctor Reacts, we dive into the revealing and controversial pricing strategy of Pfizer’s COVID-19 antiviral treatment, Paxlovid. Pfizer has unveiled a nearly $1,400 price tag for a five-day course of this crucial antiviral, ushering in a series of questions and debates regarding pharmaceutical practices, accessibility, and the business dynamics in play during a global pandemic.

Please SUBSCRIBE for new videos every Monday afternoon and Thursday Evening https://www.drberrypierre.com/YTsubscription​

Let’s Connect:

Instagram

TikTok

Lunch and Learn Patreon Family

Key Discussion Points:

• Business as Usual for Pharmaceutical Companies: A Critical Look at Pfizer’s Approach, aligning it within broader pharmaceutical industry trends and assessing whether this move echoes conventional profit-driven tactics.
• The New Pricing Structure: What’s the Timeline?: Unraveling when this new pricing will be instituted, and the anticipated immediate effects on the access and distribution of the antiviral.
• Dissecting the Impact: Insured vs. Uninsured: A detailed breakdown of how this pricing strategy impacts different segments of society, delineating between the experiences of insured individuals compared to those without insurance.

LINKS:

• Pfizer’s Price Setting of Paxlovid